Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate

Fertility and Sterility

Volumn 76, Issue 1, 2001, Pages 25-31

  Pickar, James H ^a   Yeh, I Tien ^b   Wheeler, James E ^c   Cunnane, Mary F ^d   Speroff, Leon ^e  

^a WYETH AYERST RESEARCH   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Conjugated equine estrogens (CEE); Endometrial hyperplasia; Hormone replacement therapy (HRT); Lower HRT doses; Medroxyprogesterone acetate (MPA); Menopause; Postmenopausal women; Women's HOPE Study

Indexed keywords

CALCIUM CARBONATE; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; ARTICLE; BIOPSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGING; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOMETRIAL HYPERPLASIA; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HORSES; HUMANS; INCIDENCE; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED;

EID: 0034955472     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(01)01828-3     Document Type: Article

References (28)

1. Hormone replacement therapy and endometrial cancer risk; a meta-analysis
2. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement
3. Replacement estrogens and endometrial cancer
4. Estrogens and endometrial cancer in a retirement community
5. Endometrial hyperplasia in women on cyclic or continuous estrogen regimens
6. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
7. Genital neoplasia
8. Long-term transdermal estradiol therapy; effects on endometrial histology and bleeding patterns
9. A prospective 1-year study of estrogen and progestin in postmenopausal women; effects on the endometrium
10. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone
11. Effects of hormone replacement therapy on the endometrium and lipid parameters; a review of randomized clinical trials, 1985 to 1995
12. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens; results of a prospective study
13. Cancer of the uterine corpus
14. Endometrial hyperplasia and related cellular changes
15. The behavior of endometrial hyperplasia. A long-term study of 'untreated' hyperplasia in 170 patients
16. Personal perspective on low-dosage estrogen therapy for postmenopausal women
17. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding
18. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism
19. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate
20. Agreement in assessing endometrial pathology; the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
21. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens
22. Low-potency oestrogen and risk of endometrial cancer; a case-control study
23. The effect of interobserver variation in dating endometrial histology on the diagnosis of luteal phase defects
24. Error in histologic dating of secretory endometrium; variance component analysis
25. Observer variability in endometrial cytology using kappa statistics
26. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens
27. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma
28. Evaluation of the impact of intraobserver variability on endometrial dating and the diagnosis of luteal phase defects